Ziopharm Oncology IN (ZIOP)

$2.26 0.17 (7.00%)

19:29 EDT ZIOP Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 321.82M

PE Ratio -4.26

EPS -0.53

Volume (Avg. Vol.) 1.78M

Day's Range 2.25 - 2.44

52-Week Range 1.79 - 5.61

Dividend & Yield N/A (N/A)

ZIOP Stock Predictions, Articles, and Ziopharm Oncology IN News

From the Web

Ziopharm Oncology Inc (ZIOP) Q2 2020 Earnings Call Transcript

From The Motley Fool Aug 7, 2020

ZIOP earnings call for the period ending July 30, 2020.

Technical Short Put Spread Fade the Dip Trade and Trigger in ZIOPHARM Oncology Inc

From Capital Market Laboratories Jul 29, 2020

The Techncial Trigger Driven Option Trade Right Before ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Earnings.

Why Ziopharm Oncology Shares Zoomed Higher Today

From The Motley Fool Sep 14, 2020

One of the biotech's pipeline candidates won a key FDA designation.

January 2023 Options Now Available For ZIOPHARM Oncology (ZIOP)

From Market News Video Sep 14, 2020

Investors in ZIOPHARM Oncology Inc (ZIOP) saw new options become available today, for the January 2023 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Ziopharm Oncology nabs rare pediatric disease tag for brain tumor gene therapy (NASDAQ:ZIOP)

From Seeking Alpha Sep 14, 2020

The FDA has granted Rare Pediatric Disease Designation to Ziopharm Oncology's (ZIOP) veledimex (Controlled IL-12) with Ad-RTS-hIL-12, for the treatment of diffuse intrinsic pontine glioma (DIPG), a type of brain tumor occurring in the pontine region of the brain (acts as a control center for the regulation of a number of vital functions).DIPG accounts for ~10%-15% of all cases of brain tumors in children.Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12), a master-regulator of the immune system.Controlled IL-12 is currently in a Phase 1/2 trial to evaluate the safety and tolerability of a single intratumoral injection of Ad-RTS-hIL-12 given with up to 14 days of oral veledimex in children with gliomas.

81 Biggest Movers From Yesterday

From Benzinga Aug 13, 2020

Gainers India Globalization Capital, Inc. (NYSE: IGC) shares surged 300.4% to close at $2.56 on Wednesday said the FDA notified on July 30 that it has authorized the company to...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell